Kaplan-Meier Plotter survival analysis showed that breast cancer patients with low expression of ZMYND11 had worse OS (Fig. 6C), RFS (Fig. 6D), distant metastasis-free survival (DMFS, Fig. 6E) and post-progression survival (PPS, Fig. 6F) than those with high expression. This evidence concerns the gene ZMYND11 and breast carcinoma.